Penbrook Management LLC Sells 16,200 Shares of Mesoblast Limited (NASDAQ:MESO)

Penbrook Management LLC lessened its position in Mesoblast Limited (NASDAQ:MESO - Free Report) by 15.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 91,075 shares of the company's stock after selling 16,200 shares during the period. Mesoblast comprises about 1.2% of Penbrook Management LLC's portfolio, making the stock its 13th largest holding. Penbrook Management LLC owned 0.08% of Mesoblast worth $1,803,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. R Squared Ltd acquired a new stake in Mesoblast during the fourth quarter worth approximately $30,000. Signaturefd LLC lifted its holdings in Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company's stock worth $45,000 after purchasing an additional 3,099 shares during the last quarter. Perkins Coie Trust Co boosted its stake in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock valued at $94,000 after purchasing an additional 1,500 shares during the period. XTX Topco Ltd acquired a new position in Mesoblast in the 2nd quarter valued at $103,000. Finally, GAMMA Investing LLC increased its position in Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock worth $133,000 after acquiring an additional 1,213 shares during the period. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Price Performance

Shares of MESO stock traded up $0.10 on Monday, hitting $20.24. 187,827 shares of the company's stock were exchanged, compared to its average volume of 473,291. Mesoblast Limited has a 12 month low of $1.75 and a 12 month high of $22.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The company has a 50 day moving average of $15.67 and a 200 day moving average of $10.62.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MESO. Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. Piper Sandler increased their price objective on shares of Mesoblast from $11.00 to $15.00 and gave the stock an "overweight" rating in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a research report on Thursday. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.50.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.